Association between clinical characteristics (categorical variables) and fecal calprotectin concentration at IMDC onset (N=77)
| Characteristics | n (%) | FC concentration (μg/g), mean±SD | P value* |
| Diarrhea CTCAE grade | 0.391 | ||
| 1–2 | 25 (32) | 397±57 | |
| 3–4 | 52 (68) | 464±47 | |
| Colitis CTCAE grade | 0.509 | ||
| 1–2 | 40 (52) | 419±51 | |
| 3–4 | 37 (48) | 468±54 | |
| Endoscopic presentation | 0.008 | ||
| Mucosal inflammation | 19 (25) | 641±71 | |
| Non-ulcerative inflammation | 38 (49) | 438±54 | |
| Normal | 20 (26) | 263±44 | |
| Histologic features | 0.025 | ||
| Acute active colitis | 14 (18) | 512±96 | |
| Chronic active colitis | 44 (57) | 495±50 | |
| Microscopic colitis | 19 (25) | 270±46 |
*Based on t-test for two-group comparison and one-way analysis of variance for three-group comparison.
CTCAE, Common Terminology Criteria for Adverse Events; FC, fecal calprotectin; IMDC, immune-mediated diarrhea and colitis.